UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2009

ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware

0-21696

22-3106987

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts	02139
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 494-0400

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On November 5, 2009, ARIAD Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2009, and an update on corporate developments. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Except for the information set forth under the headings “Upcoming Medical Meetings” and “Upcoming Investor and Partnering Meetings,” the information contained in the press release shall be considered “filed” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall be incorporated by reference into filings of the Company under the Securities Act of 1933, as amended (the “Securities Act”).

In the press release dated November 5, 2009 attached hereto as Exhibit 99.1, the Company provided information on upcoming medical and investor and partnering meetings. The information set forth under the headings “Upcoming Medical Meetings” and “Upcoming Investor and Partnering Meetings” in the press release attached hereto as Exhibit 99.1 is being furnished pursuant to this Item 7.01 of this Current Report on Form 8-K, and shall not be incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Exhibit Number	Description

99.1	Press Release dated November 5, 2009 regarding the Company’s earnings as of and for the three and nine month periods ended September 30, 2009.

Except for the information set forth under the headings “Upcoming Medical Meetings” and “Upcoming Investor and Partnering Meetings,” the information contained in Exhibit 99.1 shall be considered “filed” under the Exchange Act and shall be incorporated by reference into filings of the Company under the Securities Act. The information set forth under the headings “Upcoming Medical Meetings” and “Upcoming Investor and Partnering Meetings” in Exhibit 99.1 is being furnished and shall not be incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ARIAD Pharmaceuticals, Inc.


		By:	/s/ Edward M. Fitzgerald
			Edward M. Fitzgerald
			Senior Vice President, Chief Financial Officer


Date:	November 5, 2009